Tegaserod


Tegaserod

drugbox
IUPAC_name = 2-((5-Methoxy-1"H"-indol-3-yl)methylene)-"N"-pentylhydrazinecarboximidamide




width = 143px
CAS_number = 189188-57-6
ATC_prefix = A03
ATC_suffix = AE02
PubChem = 6918369
DrugBank = APRD00096 (wrong structure)
C = 16 | H = 23 | N = 5 | O = 1
molecular_weight = 301.39 g/mol
smiles = CCCCCN=C(/N)N/N=C/c1c [nH] c2ccc(CO)cc12
bioavailability = 10%
protein_bound = 98%
metabolism = Gastric and hepatic
elimination_half-life = 11 ± 5 hours
excretion = Fecal and renal
pregnancy_AU = B3
pregnancy_US = B
legal_status = Withdrawn
routes_of_administration = Oral

Tegaserod is a 5-HT4 agonist manufactured by Novartis and used for the management of irritable bowel syndrome and constipation. [cite web|url=http://www.pharma.us.novartis.com/newsroom/pressReleases/releaseDetail.jsp?PRID=2004 |title= New Data for Zelnorm |accessmonthday= March 30 |accessyear = 2007] Its use was the only drug approved by the United States Food and Drug Administration to help relieve the abdominal discomfort, bloating and constipation associated with irritable bowel syndrome. Its use was also approved to treat chronic idiopathic constipation. [cite web|url=http://www.fda.gov/bbs/topics/ANSWERS/2002/ANS01160.html |title=FDA approves first treatment for women with irritable-bowel syndrome |accessmonthday= March 30 |accessyear= 2007] It is currently marketed by Novartis under the trade names Zelnorm and Zelmac in the United States and abroad, respectively.

Mechanism of action

The drug functions as a motility stimulant, achieving its desired therapeutic effects through activation of the 5-HT4 receptors of the enteric nervous system in the gastrointestinal tract. It also stimulates gastrointestinal motility and the peristaltic reflex, and allegedly reduces abdominal pain. [cite book |last=Rossi |first=S. |title=Australian Medicines Handbook |year=2004 |publisher=Health Communication Network |location=Adelaide |isbn=ISBN 0-9578521-4-2 ] Additionally, tegaserod is a 5-HT2B receptor antagonist.cite journal |author=Beattie DT, Smith JA, Marquess D, "et al" |title=The 5-HT4 receptor agonist, tegaserod, is a potent 5-HT2B receptor antagonist in vitro and in vivo |journal=Br. J. Pharmacol. |volume=143 |issue=5 |pages=549–60 |year=2004 |month=November |pmid=15466450 |pmc=1575425 |doi=10.1038/sj.bjp.0705929 |url=http://dx.doi.org/10.1038/sj.bjp.0705929]

Withdrawal from market

On March 30 2007, the U.S. Food and Drug Administration requested that Novartis withdraw Zelnorm from shelves. The FDA alleges a relationship between prescriptions of the drug and increased risks of heart attack or stroke. [cite web|url= http://www.cnn.com/2007/HEALTH/03/30/constipation.drug.ap/|title= Constipation drug pulled at FDA request |accessmonthday= March 30 |accessyear= 2007] An analysis of data collected on over 18,000 patients demonstrated adverse cardiovascular events in 13 of 11,614 patients treated with Zelnorm (a rate of 0.11%) as compared with 1 of 7,031 patients treated with placebo (a rate of 0.01%). Novartis alleges all of the affected patients had preexisting cardiovascular disease or risk factors for such, and further alleges that no causal relationship between tegaserod use and cardiovascular events has been demonstrated. [cite web | url = http://www.zelnorm.com/Zelnrom_PR_US_330_Final_12_1007.pdf | title = Zelnorm | publisher = Novartis | accessdate = 2007-03-30] On the same day as the FDA announcement, Novartis Pharmaceuticals Canada announced that it was suspending marketing and sales of the drug in Canada in response to a request from Health Canada. [cite web |url=http://www.newswire.ca/en/releases/archive/March2007/30/c9000.html |title=Novartis suspends Canadian marketing and sales of Zelnorm in response to request from Health Canada |accessdate= 2007-03-30 ] Some manufacturers in India, such as Cipla, seem to still have generic Tegaserod available in their listings [ [http://www.cipla.com/ourproducts/productlist/t.htm Cipla - Product List ] ] and some online merchants may be selling it.

References

http://hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/2007/zelnorm_pc-cp_2_e.html

External links

* [http://www.zelnorm.com Manufacturer's website]


Wikimedia Foundation. 2010.

Look at other dictionaries:

  • Tegaserod — Identificadores Código ATC  ? Datos químicos Fórmula  ? Datos clínicos Cat. e …   Wikipedia Español

  • tegaserod — noun A particular drug used to treat irritable bowel syndrome and constipation …   Wiktionary

  • tegaserod maleate — teg·a·ser·od maleate (teg″ə serґod) a selective serotonin antagonist, used in the treatment of irritable bowel syndrome and other gastrointestinal motility disorders. It has been withdrawn from the market in the United States …   Medical dictionary

  • Irritable bowel syndrome — This article is about a functional disorder. For bowel inflammation, see Inflammatory bowel disease. Irritable bowel syndrome Classification and external resources ICD 10 K58 ICD 9 …   Wikipedia

  • Laxative — Laxatives (purgatives, aperients) are foods, compounds, or drugs taken to induce bowel movements or to loosen the stool, most often taken to treat constipation. Certain stimulant, lubricant, and saline laxatives are used to evacuate the colon for …   Wikipedia

  • Metoclopramide — Systematic (IUPAC) name 4 amino 5 chloro N (2 (di …   Wikipedia

  • Cisapride — Systematic (IUPAC) name (±) cis 4 amino 5 chloro N (1 [3 (4 fluorop …   Wikipedia

  • Cilansetron — Systematic (IUPAC) name (10R) 10 [(2 methyl 1H imidazol 1 yl)methyl] 5,6,9,10 tetrahydro 4H pyrido(3,2,1 jk)carbazol 11 one Clinical data …   Wikipedia

  • 5-HT3 antagonist — 5 HT3 receptor antagonists Drug class Skeletal formula of ondansetron, the prototypical 5 HT3 antagonist ATC code A04AA …   Wikipedia

  • Mosapride — Systematic (IUPAC) name (RS) 4 amino 5 chloro 2 ethoxy N {[4 (4 fluorobenzyl)morpholin 2 yl]methyl}benzamide Clinical data AHFS/Dr …   Wikipedia


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.